IGMS - IGM Biosciences

-

$undefined

N/A

(N/A)

IGM Biosciences NasdaqGS:IGMS IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M antibodies for the treatment of cancer and autoimmune and inflammatory diseases. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.

Location: 325 East Middlefield Road, Mountain View, CA, 94043, United States | Website: https://igmbio.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

-37.22M

Cash

152.1M

Avg Qtr Burn

-35.77M

Short % of Float

7.68%

Insider Ownership

37.57%

Institutional Own.

47.29%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
IGM-7354 (IL-15 x PD-L1) Details
Solid tumor/s, Cancer, Hematologic malignancies

Phase 1

Update

Phase 1

Update

Aplitabart (IGM-8444) + birinapant Details
Hematologic malignancies, Solid tumor/s

Phase 1

Update

Phase 1

Update

Imvotamab (IGM-2323) (CD20 x CD3) Details
Cancer, Chronic lymphocytic leukemia, Non-Hodgkin lymphoma

Failed

Discontinued

Imvotamab (IGM-2323) (CD20 x CD3) Details
Systemic lupus erythematosus, Autoimmune disease

Failed

Discontinued

Imvotamab (IGM-2323) (CD20 x CD3) Details
Autoimmune disease, Rheumatoid arthritis

Failed

Discontinued

Imvotamab (IGM-2323) (CD20 x CD3) Details
Idiopathic inflammatory myopathy / myositis

Failed

Discontinued

Failed

Discontinued

IGM-6268 Details
Solid tumor/s, Cancer

Failed

Discontinued